Wall Street analysts expect Heat Biologics Inc (NASDAQ:HTBX) to announce sales of $920,000.00 for the current quarter, according to Zacks. Two analysts have made estimates for Heat Biologics’ earnings. The highest sales estimate is $1.10 million and the lowest is $740,000.00. Heat Biologics reported sales of $2.06 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 55.3%. The business is expected to announce its next quarterly earnings report on Thursday, March 26th.

On average, analysts expect that Heat Biologics will report full-year sales of $2.50 million for the current fiscal year, with estimates ranging from $2.10 million to $2.89 million. For the next fiscal year, analysts forecast that the company will report sales of $2.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Heat Biologics.

NASDAQ:HTBX remained flat at $$0.47 during mid-day trading on Thursday. The company had a trading volume of 80,231 shares, compared to its average volume of 403,018. Heat Biologics has a 52 week low of $0.35 and a 52 week high of $1.80. The firm has a market cap of $16.01 million, a price-to-earnings ratio of -0.52 and a beta of 1.80. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.29 and a quick ratio of 3.29. The firm’s 50-day moving average is $0.46 and its 200 day moving average is $0.59.

An institutional investor recently raised its position in Heat Biologics stock. Vanguard Group Inc. increased its holdings in Heat Biologics Inc (NASDAQ:HTBX) by 6.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,327,660 shares of the biopharmaceutical company’s stock after acquiring an additional 84,400 shares during the quarter. Vanguard Group Inc. owned about 3.90% of Heat Biologics worth $909,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 4.93% of the company’s stock.

About Heat Biologics

Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.

Recommended Story: How do buyers and sellers choose a strike price?

Get a free copy of the Zacks research report on Heat Biologics (HTBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.